SeeThruEquity Issues Update on Amarantus Bioscience Holdings, Inc. (OTC PINK: AMBS)

NEW YORK, NY / ACCESSWIRE / December 21, 2017 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update on Amarantus Bioscience Holdings, Inc. (OTC PINK: AMBS).

The report is available here: AMBS December 2017 Update Note.

Based in San Francisco, CA, Amarantus Bioscience Holdings, Inc. (OTC: AMBS, “Amarantus”) is a biotechnology company developing treatments and diagnostics for diseases in orphan neurologic, regenerative medicine and ophthalmic therapies, through three wholly-owned subsidiary companies. The company’s Elto Pharma subsidiary has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson’s disease levodopa-induced dyskinesia (PD-LID), Alzheimer’s aggression and adult ADHD. Amarantus has also acquired the rights to the Engineered Skin Substitute program (ESS), a Phase 3 ready regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture, which is being pursued by its subsidiary Cutanogen Corporation. Amarantus’ subsidiary MANF Therapeutics, Inc. is developing pre-clinical products as treatments for brain and ophthalmic disorders, which were discovered by CEO John Commissiong, PhD using its proprietary discovery engine PhenoGuard. AMBS also owns approximately 80 million shares of Avant Diagnostics, Inc. (OTC: AVDX) via the sale of its wholly-owned subsidiary Amarantus Diagnostics, Inc. that occurred in May 2016.

Highlights from the update note include:

We are updating our coverage of Amarantus following recent events, which included a plan for recapitalization plan and clinical update covering the company’s most advanced programs. Highlights of recent activities include:

Amarantus has disclosed a plan to move forward, restarting company activities in January 2018 with an aim to monetize its subsidiary companies through Reg A+ listings on Nasdaq CM or NYSE American, beginning with Elto Pharma, or other strategic transactions.
Amarantus has reached an agreement with holders of its senior secured convertible debt and convertible preferred securities to forbear the default provisions in these instruments and temporarily cease conversion of common shares.
As part of the agreement Amarantus will deliver to old debtholders its 80mn shares of Avant Diagnostics (AVDX) in a special purpose vehicle to be liquidated in an orderly fashion.
AMBS’ Elto Pharma subsidiary is preparing to restart its Phase 2b clinical trial for small molecule Eltoprazine for Parkinson’s disease levodopa-induced dyskinesia (PD-LID). Elto Pharma also has a Phase 3 ready program for Eltoprazine for treatment of agitation in dementia and in adult ADHD.
The company estimates the combined market opportunity for these two programs is in excess of $8 billion per year, based on the patient population and prices of comparable drugs on the market.

Updating Price Target to $0.65

We are updating the price target of AMBS following recent developments at the company. The target is based on the potential value from advancing candidates at Elto Pharma and Cutanogen, taking into consideration the liabilities at the AMBS level. We see the AMBS as a high risk, high potential reward company emerging from distressed status.

Please review important disclosures on our website at www.seethruequity.com.

About Amarantus Bioscience Holdings, Inc.

Amarantus Bioscience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases through its subsidiaries. AMBS’ wholly-owned subsidiary Elto Pharma, Inc. has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson’s disease levodopa-induced dyskinesia, Alzheimer’s aggression and adult ADHD. AMBS acquired the rights to the Engineered Skin Substitute program (ESS), a regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture that is being pursued by AMBS’ wholly-owned subsidiary Cutanogen Corporation. AMBS’ wholly-owned subsidiary MANF Therapeutics, Inc. owns key intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor (MANF). MANF Therapeutics, Inc. is developing MANF-based products as treatments for brain and ophthalmic disorders. MANF was discovered by the Company’s Chief Scientific Officer John Commissiong, PhD. Dr. Commissiong discovered MANF from AMBS’ proprietary discovery engine PhenoGuard. AMBS also owns approximately 80 million shares of Avant Diagnostics, Inc. via the sale of its wholly-owned subsidiary Amarantus Diagnostics, Inc. that occurred in May 2016. www.Amarantus.com.

About SeeThruEquity

Since its founding in 2011, SeeThruEquity has been committed to its core mission: providing impactful, high quality research on underfollowed smallcap and microcap equities. SeeThruEquity has pioneered an innovative business model for equity research that is not paid for and is unbiased. SeeThruEquity is the host of acclaimed investor conferences that are the ultimate event for publicly traded companies with market capitalizations less than $1 billion.

SeeThruEquity is approved to contribute its research reports and estimates to Thomson One Analytics (First Call), the leading estimates platform on Wall Street, as well as Capital IQ and FactSet. SeeThruEquity maintains one of the industry’s most extensive databases of opt-in institutional and high net worth investors. The firm is headquartered in Midtown Manhattan in New York City.
For more information visit www.seethruequity.com.

For more information visit www.seethruequity.com.

Contact:

SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 484771